(Reuters) - Pfizer Inc said on Monday U.S. regulators declined to approve the company's biosimilar of Roche's blockbuster treatment for breast cancer, Herceptin, and sought additional technical information.
from Reuters: Health News https://ift.tt/2HkIl4F
via IFTTT
from Reuters: Health News https://ift.tt/2HkIl4F
via IFTTT
Post a Comment